11 recruiting, 6 not yet recruiting, 1 active not recruiting. 13 Phase 2, 6 Phase 1, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 8, Not yet recruiting 4, Active not recruiting 1 |
| Phase 1 | 6 | Recruiting 5, Not yet recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Adebrelimab Injection: new trials by email Literature Review of Adebrelimab Injection trials Research Report on Adebrelimab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC HS-20093 for Injection, ZG006, Adebrelimab Injection - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 338 | 2026-11-15 | 2026-10-23 |
| A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations HS-20093 for Injection, Adebrelimab Injection - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 76 | 2026-10-08 | 2026-10-23 |
| A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets - Triple Negative Breast Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1000 | 2026-09-02 | 2026-09-09 |
| Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Adebrelimab Injection, Dalpiciclib Isethionate, Cisplatin - HNSCC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 32 | 2026-09-01 | 2026-08-21 |
| A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma SHR-8068 Injection, Adebrelimab Injection, Apatinib Mesylate Tablets - Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk | Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 120 | 2026-07-01 | 2026-07-02 |
| Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Adebrelimab Injection - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-sen University | 42 | 2026-06-17 | 2026-06-10 |
| Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD Adebrelimab Injection, Apatinib Mesylate Tablets - Small Cell Lung Carcinoma | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 44 | 2026-01-31 | 2026-01-22 |
| A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) SHR-8068 Injection, Adebrelimab Injection, Gemcitabine Hydrochloride for Injection - Advanced Biliary Tract Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 604 | 2026-01-21 | 2026-01-28 |
| A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer Adebrelimab Injection, SHR-A1811 for Injection, SHR-A1904 for Injection - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 200 | 2025-08-28 | 2026-01-09 |
| A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer SHR-8068 Injection, Adebrelimab Injection, Bevacizumab Injection - Colorectal Cancer | Phase 2 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 103 | 2025-07-22 | 2026-08-11 |
| A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer SHR-A1811, Carboplatin, Bevacizumab - Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 150 | 2025-03-18 | 2026-09-11 |
| A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors SHR-1826, SHR-4642, SHR-9839 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 876 | 2025-02-18 | 2025-12-03 |
| A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma SHR-A2102, Adebrelimab injection, SHR-8068 injection - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 90 | 2024-11-04 | 2024-11-18 |
| Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection - Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 42 | 2024-10-01 | 2024-09-19 |
| Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin - Small Cell Lung Cancer | Not applicable | Recruiting | Yunpeng Liu | 38 | 2024-08-09 | 2025-01-06 |
| A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer Adebrelimab - Gastric Cancer | Phase 1 / Phase 2 | Recruiting | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 52 | 2024-08-03 | 2025-01-15 |
| A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection - Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 248 | 2024-07-30 | 2025-12-23 |
Carcinoma, Non-Small-Cell Lung (3) · Small Cell Lung Carcinoma (3) · Stomach Neoplasms (2) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (8) · Hansoh BioMedical R&D Company (2) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center (1) · Peking University Cancer Hospital & Institute (1) · Shanghai Zhongshan Hospital (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Yunpeng Liu (1)
China (15)
Jun Zhao (1) · Xiujuan Qu (1)